Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison

Atyr PHARMA (NASDAQ:ATYR) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Atyr PHARMA and Quince Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$350,000.00	805.82	-$50.39 million	($0.94)	-3.57
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.69

Quince Therapeutics has lower revenue, but higher earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Atyr PHARMA and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
Quince Therapeutics	N/A	-53.27%	-22.73%

Insider & Institutional Ownership

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Atyr PHARMA has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Atyr PHARMA and Quince Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	4	0	3.00
Quince Therapeutics	0	0	2	2	3.50

Atyr PHARMA presently has a consensus price target of $19.25, indicating a potential upside of 472.92%. Quince Therapeutics has a consensus price target of $8.50, indicating a potential upside of 304.76%. Given Atyr PHARMA’s higher probable upside, research analysts clearly believe Atyr PHARMA is more favorable than Quince Therapeutics.

About Atyr PHARMA

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.